Clinical Observation On The Treatment Of Spleen And Kidney Deficiency And Phlegm And Turbidity Stagnation Syndrome Of Chronic Renal Failure With Jiang Zhuo Decoction

Objective:through systematic research and analysis of material soup decoction of the clinical trial effect for the treatment of chronic renal failure. To explore the role of traditional Chinese medicine medicinal broth slow progress in renal insufficiency, and provide clinical basis for combining traditional Chinese and western medicine treatment of the disease.Methods:according to the standard, in conditions turbidity block will stasis, spleen kidney Yang deficiency type of 60 patients were divided into two groups, the treatment group of 30 patients, control group patients for 30 cases. Both groups on the general treatment, take material soup treatment of TCM and treatment group, control g roup oral proprietary Chinese medicine treatment, uric poisonous clear particles for treatment of 8 weeks, with patients’main clinical symptoms, to carry on the quantitative evaluation of syndromes, and prescribed checks blood Rt series (blood analysis) and renal function and serum ions such as western medicine laboratory index, the light of the main symptoms of the subjects before and after the medicine integral, laboratory test results before and after the treatment, statistical treatment and outcome.Results:the oral material treatment of chronic renal failure and blood stasis soup turbidity block, the total effective rate of patients with spleen and kidney Yang deficiency type, there are no obvious adverse reactions during the drug treatment cases. After treatment in patients with serum creatinine was lower (P< 0.05), the endogenous creatinine clearance was ascending (P< 0.05), the hemoglobin, red blood cell count, erythrocyte hematocrit higher than before treatment (P< 0.05). The patient’s blood calcium, blood phosphorus and potassium are compared with the previous no obvious fluctuation (P> 0.05).Conclusion:material soup can slow progression, and significantly reduce or eliminate clinical symptoms. And can improve patients’renal function and anemia, delay the progression of deterioration, protection of residual renal unit, improve the quality of life, reduce the incidence of end-stage uremia, reduce the case fatality rate, thus improve the survival rate.